Sometimes product defects are noticed on preparation or quality control testing of radiopharmaceuticals or unusual biodistribution may be noted during scanning of patients. Although product defects are rare, it is still important to record any defects or unusual biodistribution observed. This is to enable us to keep comprehensive information and to help identify trends that may impact patient care or safety.
The UK Radiopharmacy Group act as coordinator for the collation of data relating to defective radiopharmaceutical products and patient adverse reactions. This data is carefully scrutinised and acts as a means of informing the UK Nuclear Medicine community of potentially serious defects in products as well as a compendium of drug interactions and reactions which are published on an annual basis in the European Journal of Nuclear Medicine and Molecular Imaging.